TheraRadar
Data updated: May 26, 2026

Proquad (measles, mumps, rubella and varicella virus vaccine live)

Approved 2005-09-05
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
20
Years on Market

Details

Status
Prescription
First Approved
2005-09-05
Revenue
$594M (Q4-2024)

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
Subcutaneous, Intramuscular
Dosage Forms
For Injection

Companies

Merck
Active Ingredient: Measles, Mumps, Rubella and Varicella Virus Vaccine Live , Measles, Mumps, Rubella and Varicella Virus Vaccine Live

Proquad Approval History

2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2005 to 2005
Sep 2005 ORIGINAL
Update · CBER biologic (Purple Book)

What Proquad Treats

1 FDA approvals

Originally approved for its first indication in 2005 .

  • Other (1)
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT01621802 results posted 115158 2011-004638-32 Ph 3 completed Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

Proquad FDA Label Details

Pro Intelligence Preview

Deep insights for Proquad

Revenue Insights

  • • Q4-2024: $594M
  • • Historical trend analysis

Patent Timeline

  • • Patent expiration dates
  • • Generic/biosimilar risk

Trial Analysis

  • • Clinical trial tracking
  • • Development stage analysis

Competitive Landscape

  • • Competitor tracking
  • • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

FDA Approval: BLA125108 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.